Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Pharma Mar SA ( (ES:PHM) ) has provided an update.
Pharma Mar SA announced that its Chairman and Chief Financial Officer will present to shareholders at the Ordinary General Meeting in Colmenar Viejo, Madrid. This meeting is significant for stakeholders as it provides insights into the company’s current operations and future strategies.
The most recent analyst rating on (ES:PHM) stock is a Buy with a EUR108.00 price target. To see the full list of analyst forecasts on Pharma Mar SA stock, see the ES:PHM Stock Forecast page.
More about Pharma Mar SA
Pharma Mar SA is a biopharmaceutical company focusing on the discovery and development of marine-derived drugs for oncology treatment. The company is a leader in the biotechnology industry, with a strong emphasis on innovation and research in cancer therapeutics.
Average Trading Volume: 65,804
Technical Sentiment Signal: Buy
Current Market Cap: €1.47B
For an in-depth examination of PHM stock, go to TipRanks’ Overview page.